Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pre-exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents.
Mauro FR, Visentin A, Giannarelli D, Molinari MC, Proietti G, Petrella M, Angotzi F, Pepe S, Trentin L, Baroncelli S, Giombini E, Meschi S, Maggi F, Focosi D. Mauro FR, et al. Among authors: proietti g. Br J Haematol. 2023 May;201(3):564-567. doi: 10.1111/bjh.18701. Epub 2023 Feb 22. Br J Haematol. 2023. PMID: 36810731 No abstract available.
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study.
Mauro FR, Giannarelli D, Galluzzo CM, Visentin A, Frustaci AM, Sportoletti P, Vitale C, Reda G, Gentile M, Levato L, Murru R, Armiento D, Molinari MC, Proietti G, Pepe S, De Falco F, Mattiello V, Barabino L, Amici R, Coscia M, Tedeschi A, Girmenia C, Trentin L, Baroncelli S. Mauro FR, et al. Among authors: proietti g. Cancers (Basel). 2023 May 30;15(11):2993. doi: 10.3390/cancers15112993. Cancers (Basel). 2023. PMID: 37296954 Free PMC article.
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
Visentin A, Mauro FR, Scarfò L, Gentile M, Farina L, Reda G, Ferrarini I, Proietti G, Derenzini E, Cibien F, Vitale C, Sanna A, Pietrasanta D, Marchetti M, Murru R, Rigolin GM, Sportoletti P, Trimarco V, Cavarretta CA, Angotzi F, Cellini A, Ruocco V, Zatta I, Laurenti L, Molica S, Coscia M, Ghia P, Foà R, Cuneo A, Trentin L. Visentin A, et al. Among authors: proietti g. Am J Hematol. 2023 Sep;98(9):E237-E240. doi: 10.1002/ajh.27009. Epub 2023 Jun 29. Am J Hematol. 2023. PMID: 37382471 No abstract available.
Publisher Correction: Suspect screening analysis to improve untargeted and targeted UHPLC-qToF approaches: the biodegradability of a proton pump inhibitor medicine and a natural medical device.
Mattoli L, Proietti G, Fodaroni G, Quintiero CM, Burico M, Gianni M, Giovagnoni E, Mercati V, Santi C. Mattoli L, et al. Among authors: proietti g. Sci Rep. 2024 Mar 7;14(1):5660. doi: 10.1038/s41598-024-53924-1. Sci Rep. 2024. PMID: 38454019 Free PMC article. No abstract available.
Optimal management of patients after acute coronary syndrome.
Panattoni G, Monzo L, Gugliotta M, Proietti G, Tatangelo M, Jacomelli I, Zimbardo G, Meringolo F, Fedele E, Calò L. Panattoni G, et al. Among authors: proietti g. Eur Heart J Suppl. 2023 Apr 26;25(Suppl C):C84-C89. doi: 10.1093/eurheartjsupp/suad039. eCollection 2023 May. Eur Heart J Suppl. 2023. PMID: 37125273 Free PMC article.
A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency.
Visentin A, Molinari MC, Pravato S, Cellini A, Angotzi F, Cavaretta CA, Ruocco V, Imbergamo S, Piazza F, Proietti G, Mauro FR, Trentin L. Visentin A, et al. Among authors: proietti g. Curr Oncol. 2022 Dec 25;30(1):274-283. doi: 10.3390/curroncol30010022. Curr Oncol. 2022. PMID: 36661671 Free PMC article.
94 results